Skip to main navigation Skip to search Skip to main content

A Multicenter, 6-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2b Study of Daily Oral LUM-201 in Naive-to-Treatment, Prepubertal Children with GHD

Project: Research

Project Details

StatusFinished
Effective start/end date04/20/21 → 12/31/25

Funding

  • Lumos Pharma: $34,223.00